Digital Therapeutics Market to Grow with Rising Prevalence of Chronic Diseases Estimating 20.8% of CAGR by 2025 - Livongo Health, Proteus Digital Health, WellDoc, Fitbit, Omada Health

Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and account for most of the nation’s health care costs.

The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.

According to report of CDC, in 2018, approximately more than 9% of the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US. Similar trends for high presence of diabetes are prevalent around other geographies of the globe that include Asia Pacific, Europe, Middle East and Africa.

For instance, according to IDF Diabetes Atlas published by the International Diabetes Federation in 2017, south-east Asia is home to approximately one-fifth (19%) of the total diabetes population worldwide. According to the report of American College of Cardiology Foundation, in 2018, Coronary heart disease (CHD) was the leading cause of deaths attributable to cardiovascular disease (CVD) in the US, which is followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). By 2035, approximately 130 million adults in the US population are projected to have some form of CVD. Thus, increasing geriatric population and related chronic diseases are expected to propel the growth of global digital therapeutics market over the forecast years.

Get Sample report at https://www.theinsightpartners.com/sample/TIPHC00002236?utm_source=OpenPR&utm_medium=Simran

Strategic Insights

Product launch/update and partnerships were observed as the most adopted strategy in global digital therapeutics industry. Few of the product approvals and partnerships made by the players in the market are listed below:

2017: In November, Propeller Health and Express Scripts entered into a partnership to provide Propeller’s FDA-cleared digital solutions to Express Scripts to manage asthma or COPD.


2016: In November, Propeller Health received FDA approval for its Propeller platform for use with GSK’s Ellipta inhaler.

2018: In April, Canary Health entered into a partnership with NMRHCA to offer the Better Choices, Better Health (BCBH) digital therapeutics program in New Mexico.

2016: In June, Canary Health partnered with Medtronic to expand their diabetes care offerings with Canary Health's self-management suite for pre-diabetes, diabetes and related comorbidities.

DIGITAL THERAPEUTICS – MARKET SEGMENTATION
By Application
• Diabetes
• Cardiovascular Diseases
• Central Nervous System (CNS) Disease
• Respiratory Diseases
• Smoking Cessation
• Musculoskeletal Diseases
• Other Applications
By Distribution Channel
• Patients
• Providers
• Payers
• Employers
By Geography
• North America
• U.S.
• Canada
• Mexico
• Europe
• France
• Germany
• UK
• Asia Pacific (APAC)
• China
• India
• Japan
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• South America (SAM)
• Brazil

Company Profiles
• Propeller Health
• CANARY HEALTH
• Noom, Inc.
• 2Morrow Inc.
• Livongo Health
• Proteus Digital Health
• WellDoc, Inc.
• Fitbit, Inc.
• Omada Health, Inc.
• MANGO HEALTH

Check Discount at https://www.theinsightpartners.com/discount/TIPHC00002236?utm_source=OpenPR&utm_medium=Simran

Contact us –
Contact Person : Sameer Joshi
Phone : +1-646-491-9876
Email Id : sam@theinsightpartners.com
Website: https://www.theinsightpartners.com

About Us - The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

This release was published on openPR.